v3.24.1.u1
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2022 $ 17,287 $ 18 $ (4,594) $ 19,245 $ 4,784 $ (2,199) $ 33
Beginning balance (in shares) at Dec. 31, 2022   1,769          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 239 $ 0 0 0 239 0 0
Other comprehensive income (loss), net of tax (33) 0 0 0 0 (33) 0
Dividends declared (2,630) 0 0 0 (2,630) 0 0
Purchases of treasury stock (1,955) $ 0 (1,955) 0 0 0 0
Purchases of treasury stock (in shares)   (12)          
Stock-based compensation plans and other 399 $ 0 25 374 0 0 0
Stock-based compensation plans and other (in shares)   7          
Change in noncontrolling interest (4) $ 0 0 0 0 0 (4)
Ending balance at Mar. 31, 2023 13,303 $ 18 (6,524) 19,619 2,393 (2,232) 29
Ending balance (in shares) at Mar. 31, 2023   1,764          
Beginning balance at Dec. 31, 2023 10,397 $ 18 (6,533) 20,180 (1,000) (2,305) 37
Beginning balance (in shares) at Dec. 31, 2023   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 1,369 $ 0 0 0 1,369 0 0
Other comprehensive income (loss), net of tax (149) 0 0 0 0 (149) 0
Dividends declared (2,753) 0 0 0 (2,753) 0 0
Purchases of treasury stock (1,324) $ 0 (1,324) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 504 $ 0 28 476 0 0 0
Stock-based compensation plans and other (in shares)   7          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Mar. 31, 2024 $ 8,047 $ 18 $ (7,829) $ 20,656 $ (2,384) $ (2,454) $ 40
Ending balance (in shares) at Mar. 31, 2024   1,766